INTEL Logo

Intel collaborates with companies to drive high-performance computing that dramatically lowers the cost and shortens the DNA sequencing and indexing time so researchers can advance the fight against cancer and other difficult problems. A decade ago, at the dawn of the revolution in human genomics, researchers studied the DNA of the typical human. Now, they're focusing on the personal variations that can determine whether an individual has a higher risk for cancer or a genetic disease. Working with companies such as Illumina, which provides next-generation sequencing technologies, Diagnomics Inc. provides the analytical power to find variations in genes that can lead to clues about disease and personalized treatment.

Diagnomics serves Illumina, a company that develops innovative solutions for next generation genome sequencing analysis and other clinical and research customers - such as hospitals, universities, and pharmaceutical and private research companies - by processing the data of genetic sequences. To shorten the time to complete the bioinformatic the process, Diagnomics implemented HP ProLiant DL380 G8 servers based on the Intel Xeon® processor E5-2670. Diagnomics worked closely with Intel's Health Strategy and Solutions and Enterprise Solution Sales groups, which recommended a hardware configuration that would deliver the most efficient platform.

In addition, the Intel Software and Services Group provided software tools and engineers to optimize the code for the platform, further speeding the process. Team of Intel and Diagnomics engineers and scientists tested other servers and compared them to this new architecture, and they are very satisfied with the performance. The Intel Xeon® processor based servers showed a very big advantage over other solutions. The team ran an indexing process on other platform, and then on the new Intel Xeon® processor E5-2670-based platform. While the other old servers took about four days to complete the job, the new architecture took less than 11 hours. The team said the new processors reduce latency by integrating well with PCI Express controllers and solid-state drives (SSDs), speeding the time it takes to process data.

Diagnomics is also exploring how Intel's storage technologies can help the company launch a new line of business that several customers have already requested. The company is considering the Intel Solid-State Drive DC S3700 Series, a direct attach storage solution, which we think will offer faster speeds and better reliability than anything else on the market. Diagnomics' software with Intel hardware, engineers can achieve the maximum processing speed. "Ideally, we'll process genomes in a day. That's how we envision our relationship with Intel® going forward. We are working with Intel's hardware and software engineering teams to make one of the best genome analysis solutions they can bring into a clinic," said Dr. Min Lee, president of Diagnomics.

INTEL Diagnomics News